Torrent Pharma, one of India's top drug companies, plans to expand its anti-diabetes portfolio by acquiring three brands from Boehringer Ingelheim GmbH. These brands, which include Cospiaq, Cospiaq Met, and Xilingio, contain Empagliflozin, an important drug for managing type 2 diabetes.

The acquisition is expected to be completed in March 2025 and follows a co-marketing agreement that has been in effect since 2022. The diabetes market in India is growing rapidly, with projections indicating a significant increase in the number of patients by 2045. The market for Empagliflozin alone is valued at Rs 3,235 crore and is expected to grow at a compound annual growth rate of 25%.

Aman Mehta, Director of Torrent Pharma, has expressed the company's commitment to strengthening its diabetes care offerings and ensuring continued access to essential treatments for patients.